|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:DNA-dependent_DNA_polymerase
gptkb:azidothymidine_(AZT)
|
|
gptkbp:activities
|
gptkb:nucleoside_reverse_transcriptase_inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:1991
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
Videx
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
HIV/ AIDS treatment
|
|
gptkbp:contraindication
|
severe liver disease
severe renal impairment
hypersensitivity to didanosine
|
|
gptkbp:developed_by
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:discontinued
|
some countries
|
|
gptkbp:dosage_form
|
gptkb:beer
powder for oral solution
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
enteric-coated
sustained-release
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
didanosine
|
|
gptkbp:ingredients
|
C10 H12 N4 O3 S
|
|
gptkbp:interacts_with
|
gptkb:beer
other antiretroviral drugs
|
|
gptkbp:invention
|
gptkb:2006
|
|
gptkbp:is_known_for
|
dd I
|
|
gptkbp:is_used_for
|
treatment of HIV
|
|
gptkbp:lifespan
|
1.5 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:previous_name
|
gptkb:didanosine
|
|
gptkbp:provides_information_on
|
part of combination therapy
|
|
gptkbp:research_focus
|
treatment adherence
drug interactions
long-term effects
combination therapies
HIV resistance
|
|
gptkbp:safety_features
|
Category B
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
rash
lactic acidosis
peripheral neuropathy
pancreatitis
|
|
gptkbp:storage
|
room temperature
|